ChromaDex Corporation
CDXC
NASDAQ·Healthcare·Biotechnology·Mkt cap $611.9M
$7.87
▼ -0.88%
P/E
35.77
Mkt Cap
$611.9M
52-Wk Range
$2.31–$9.18
52-Week Range
$2.31 - $9.18
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 98.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary NAD+ precursor technology with NIAGEN as differentiated, patented ingredient
- Vertically integrated business model controlling research, manufacturing, and direct consumer distribution
- Established brand recognition in emerging healthy aging category with growing clinical validation
- Diversified revenue streams reducing dependency on single product or customer segment
- Recurring revenue from analytical services division providing business stability
Bear Case
2 risks
- High volatility (beta 2.2). Larger-than-normal price swings expected.
- Significant premium - growth priced in
Growth
Stable outlook
Expanding consumer demand for preventative health and longevity-focused supplements
Value
Significant premium - growth priced in
Momentum
Hot
+32.5% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CDXC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Most recent quarter reported revenue of $0 (-100% YoY). Reported EPS of $0.08.
Reported EPS · last 4Q
Q1 26
$0.08
Q4 25
$0.05
Q3 25
$0.06
Q2 25
$0.05
Revenue trend · last 8Q
—
—
+37%
+38%
-100%
-100%
-100%
-100%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$22.7M
$25.6M
$29.1M
$30.5M
$0
$0
$0
$0
Margins · last 8Q
Gross
—
Operating
—
Profit
—
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How CDXC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related